KRAS and colorectal carcinoma: Further studies into anti-tumor activities against EGFR-expressing CRC cells are necessary in order to obtain a more detailed understanding of antibody therapy against CRC cells with KRAS p.G13D, which will lead to the development of more effective clinical treatments.